Pill-based Vaccines on the Horizon

A non-biological influenza vaccine, which can be delivered in a pill form has been developed by researchers from Cardiff University. Stable at room temperature this new type of vaccine does not require refrigeration – a process that can account for most of the cost of delivery of many current vaccines.

Professor Andrew Sewell, from Cardiff University’s School of Medicine, who led the study, said: “There are many benefits to oral vaccines. Not only would they be great news for people who have a fear of needles but they can also be much easier to store and transport, making them far more suitable for use in remote locations where current vaccine delivery systems can be problematic.”

The new form of preparation was made in a novel way, by using ‘mirror images’ of the protein molecules that make up life.

Standard vaccines usually work by introducing a safe form of a germ, or a harmless part of that germ (often proteins) into our bodies. These foreign proteins stimulate our immune cells which then remember it and launch a stronger attack if they encounter it again. Normal germs or proteins would usually be digested if eaten. The new work shows that stable mirror image forms of parts of such proteins can also induce a protective immune response. These mirror image molecules cannot be digested, opening up the possibility for stable non-biologic vaccines to be supplied in pill form.

Professor Sewell explained: “The carbon molecules that form all proteins on Earth are left-handed molecules, they also have a non-biologic, right-handed form. Even though these two forms of a molecule look identical at first glance they are actually mirror images of each other, just like our right and left hands,and cannot be superimposed on each other. The left-handed forms of proteins are easily digested and do not last long in nature. The unnatural, right-handed forms of these molecules are vastly more stable.

“Our demonstration that unnatural molecules, like these mirror image molecules, can be successfully used for vaccination opens up possibilities to explore the use of other unnatural, stable molecular ‘drugs’ as vaccines in the future."

This new work provides proof-of-concept in a laboratory setting. A lot more research will be required to develop such approaches for the entire population and other diseases. It is likely to take several years before a non-biologic vaccine could be tested in humans.

Divya Shah, from Wellcome’s Infection and Immunobiology team, said: “This is a very exciting first proof of concept study that could provide a potential route to make vaccines that are thermostable and be administered orally. This could reduce the cost and increase accessibility across the globe, however much more research is needed to translate the findings into real-world vaccines.”

The Research was funded by Wellcome and BBSRC and is published in the Journal of Clinical Investigation